Search Results

You are looking at 331 - 340 of 2,881 items for :

  • Refine by Access: All x
Clear All
Full access

NCCN Task Force Report: Molecular Markers in Leukemias and Lymphomas

Jerald P. Radich, Andrew D. Zelenetz, Wing C. Chan, Carlo M. Croce, Myron S. Czuczman, Harry P. Erba, Sandra J. Horning, Jane Houldsworth, B. Douglas Smith, David S. Snyder, Hema M. Sundar, Meir Wetzler, and Jane N. Winter

with imatinib (IM) [abstract] . Blood 2008 ; 112 : Abstract 186 . 16 Kantarjian H O’Brien S Talpaz M . Outcome of patients with Philadelphia chromosome-positive chronic myelogenous leukemia post-imatinib mesylate failure . Cancer 2007

Full access

Impact of Nonadherence to NCCN Adjuvant Radiotherapy Initiation Guidelines in Head and Neck Squamous Cell Carcinoma in an Underserved Urban Population

Anusha Ponduri, David Z. Liao, Nicolas F. Schlecht, Gregory Rosenblatt, Michael B. Prystowsky, Rafi Kabarriti, Madhur Garg, Thomas J. Ow, Bradley A. Schiff, Richard V. Smith, and Vikas Mehta

in intensity-modulated radiotherapy (RT), reduction of treatment time, and combining PORT with chemotherapy make the outcomes of delayed initiation uncertain. 17 Reasons for S-PORT delay need to be investigated to identify susceptible patients and

Full access

VATS Versus Open Surgery for Lung Cancer Resection: Moving Beyond the Incision

Aaron M. Cheng and Douglas E. Wood

quality and cancer outcomes, namely cancer staging and quality of cancer surgery. Rather than debating incisions, thoracic surgeons should be advocating for specialty care and surgical quality that assures the best short- and long-term outcomes for

Full access

NCCN Guidelines Updates: Pancreatic Cancer

Margaret A. Tempero

Panel Adds to Pancreatic Cancer Recommendations For the first time in decades, advances in diagnostics and adjuvant therapies appear to be improving outcomes in pancreatic cancer. These advances are reflected in additions to the NCCN Clinical

Full access

Updates in the Management of Myelofibrosis

Presented by: Andrew T. Kuykendall

showed that overall survival in MF may be improved in the era of ruxolitinib. 4 Compared with patients who received investigational therapy or “other” treatments, patients treated with ruxolitinib had better outcomes. Additionally, those diagnosed after

Full access

New Treatment Options for the Management of Multiple Myeloma

Shaji K. Kumar

goal of therapy is to achieve a deep response while balancing toxicity, given the improved outcome in patients achieving MRD-negative status. “We still need to learn a lot about how to use MRD testing and results in the clinic,” Dr. Kumar said

Full access

Management of Patients With Nonmetastatic Prostate Cancer

Presented by: Julio M. Pow-Sang

Although localized prostate cancer is a heterogeneous disease, certain diagnostic features—pathology, imaging, and genetic profiling—can be helpful in categorizing patients into risk groups for adverse outcomes. At the NCCN 2022 Annual Conference

Full access

Physician Experience and Risk of Rituximab Discontinuation in Older Adults With Non-Hodgkin’s Lymphoma

Scott F. Huntington, Jessica R. Hoag, Rong Wang, Amer M. Zeidan, Smith Giri, Steven D. Gore, Xiaomei Ma, Cary P. Gross, and Amy J. Davidoff

association between volume of care provided and clinical outcomes. 5 – 9 Hence, it is plausible that the quality of cancer care could also be better for patients receiving complex systemic therapies at the hands of medical oncologists who have greater

Full access

A Real-World Comparison of Regorafenib and Trifluridine/Tipiracil in Refractory Metastatic Colorectal Cancer in the United States

Christopher Nevala-Plagemann, Shashank Sama, Jian Ying, Jincheng Shen, Benjamin Haaland, Vaia Florou, and Ignacio Garrido-Laguna

metastatic CRC (mCRC), fluoropyrimidine-based cytotoxic chemotherapy has long been the mainstay of treatment. 2 , 3 Improvements in clinical outcomes have been achieved by combining chemotherapy with an anti–vascular endothelial growth factor (anti

Full access

Acute and Chronic Complications After Treatment of Locoregional Anal Cancer: Prevention and Management Strategies

Leah Katz, David P. Horowitz, and Lisa A. Kachnic

experience significant acute and chronic GI symptoms related to CRT; however, a recent study using patient-reported outcomes (PROs) demonstrated that most patients return to baseline at 3 months status post CRT completion, based on the EPIC questionnaire. 28